Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eton Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eton Pharmaceuticals's regulatory disclosures and financial reporting.
Eton Pharmaceuticals entered a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), an orphan drug for various forms of leishmaniasis. The initial term runs through March 31, 2032, with options for up to ten additional one-year renewals.
Eton will pay the supplier $4.25 million in fixed fees during the initial term and up to an additional $4.0 million tied to cumulative net sales milestones of $50 million, $100 million, $150 million and $200 million. The supplier receives 55% of net sales up to $7.0 million per year and 50% above that, while covering product and regulatory costs; Eton funds sales and marketing. Eton’s exclusive U.S. rights begin on September 26, 2026, and 2025 U.S. sales of IMPAVIDO were $8.1 million.
Eton Pharmaceuticals reported a profitable quarter for the three months ended March 31, 2026, with total revenues of $24,266 and net income of $1,554, compared with a net loss a year earlier. Revenue was driven by higher product sales and royalties, especially from INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, Carglumic Acid and the addition of KHINDIVI™. Licensing revenue declined because the prior year included one-time INCRELEX® out-licensing and DS-200 milestone payments. Gross profit rose to $14,735 as product sales expanded, while operating expenses increased mainly from higher FDA fees and headcount.
Cash from operating activities strengthened to $7,405, but overall cash declined to $19,661 after $15,075 of investing outflows, largely a $14,000 upfront payment for U.S. rights to HEMANGEOL® and a $1,000 IPR&D license. The balance sheet shows $97,710 in total assets, including $43,738 of intangible assets related to acquired rare disease products, and $30,747 of SWK term debt. Management highlighted non-GAAP adjusted EBITDA of $5,709 and non-GAAP net income of $4,482, reflecting add-backs for amortization, stock-based compensation and inventory step-up.
Eton Pharmaceuticals reported strong first-quarter 2026 results, with total net revenue of $24.3 million, up 40% from $17.3 million a year earlier, and product sales and royalties rising 73% to $24.3 million. Gross profit increased to $14.7 million from $9.9 million.
The company generated Adjusted EBITDA of $5.7 million, or 24% of revenue, versus $3.7 million and 21% a year ago. GAAP results swung to net income of $1.6 million from a $1.6 million loss, while non-GAAP net income rose to $4.5 million. Eton raised its 2026 revenue outlook to more than $120 million and now targets at least a 30% Adjusted EBITDA margin, supported by record product sales, launches of DESMODA and HEMANGEOL, and continued rare-disease pipeline progress.
Eton Pharmaceuticals filed a report describing the relaunch of HEMANGEOL (propranolol) Oral Solution, the only FDA‑approved treatment for infantile hemangioma, a rare pediatric vascular tumor that can be time‑sensitive.
The relaunch integrates the full Eton Cares patient support program, including $0 co‑pay for eligible commercially insured patients and expanded patient assistance. HEMANGEOL is an orphan drug typically started between five weeks and five months of age and used for about six months to help prevent complications. The company estimates approximately 5,000–10,000 infants in the United States are treated with HEMANGEOL each year and is using an exclusive rare disease specialty pharmacy distribution model to support timely access.
Eton Pharmaceuticals filed an 8-K to announce dosing of the first patient in a pilot clinical study of ET-700, its extended-release zinc acetate candidate for Wilson disease. The double-blinded, placebo-controlled trial in Denmark will follow 36 healthy volunteers over four weeks using 64Cu PET imaging to measure intestinal copper absorption.
The study compares GALZIN 50 mg three times daily, ET-700 75 mg twice daily plus one placebo dose, and placebo three times daily, with hepatic 64Cu uptake as the primary endpoint. Eton’s CEO said that, if approved, ET-700 could potentially exceed $100 million in peak annual U.S. sales and support simpler dosing for this lifelong condition.
Eton Pharmaceuticals is holding its 2026 annual stockholders meeting virtually on June 9, 2026 at 10:00 a.m. CDT. Stockholders of record as of April 10, 2026, when 27,359,791 common shares were outstanding, can vote.
Investors are being asked to elect Jenn Adams and Charles J. Casamento as Class II directors through the 2029 meeting and to ratify Grant Thornton LLP as independent auditor for the year ending December 31, 2026. The proxy describes Eton’s staggered, largely independent board, committee structure, executive team, and pay programs, including performance-based bonuses and equity awards, along with detailed director and executive compensation and significant stockholder ownership.
Eton Pharmaceuticals director Norbert G. Riedel reported option exercises that increased his common stock holdings. On April 21, 2026, he exercised employee stock options to acquire 19,655 shares of common stock at $8.61 per share and 12,500 shares at $7.31 per share, for a total of 32,155 shares. After these transactions, he directly owns 67,155 common shares and also has 157,145 common shares held indirectly through the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as trustee.
Eton Pharmaceuticals announced a planned chief financial officer transition. Judith “Judy” Matthews has been appointed Executive Vice President, Accounting and Finance and will become Chief Financial Officer, Corporate Secretary, and Treasurer effective June 1, 2026, succeeding James Gruber. Gruber will remain CFO through May 31, 2026 and then serve under a six-month consulting agreement to support continuity.
Matthews’ compensation includes an annual base salary of $440,000, plus an annual discretionary bonus targeted at 45% of base salary, tied to corporate and/or individual performance goals approved by the board. As an inducement, she received a one-time option to purchase 37,000 shares of common stock, vesting in equal annual installments over four years, and will participate in standard executive benefit plans. The company states her selection was not made pursuant to any arrangement with another person and notes no disclosable family or related-party relationships.
Eton Pharmaceuticals entered into a sixth amendment to its credit agreement with SWK Funding LLC. The amendment lowers the loan’s interest rate from Secured Overnight Financing Rate (SOFR) plus 6.75% to SOFR plus 6.55% and reduces the SOFR floor from 5.0% to 2.75%.
The interest-only period was extended to November 2026, and Eton may choose to begin principal payments in May 2026 or defer them until November 2026. No fees were paid to SWK in connection with this amendment, and the loan’s maturity date remains in December 2027.
Eton Pharmaceuticals Inc: The Vanguard Group filed an amendment to a Schedule 13G reporting beneficial ownership of 0 shares (0%) of Common Stock following an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538, effective after the January 12, 2026 realignment.